Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases

Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases:

Abstract

Purpose of Review

Within the last two decades, the application of biologic medications for rheumatic diseases has greatly expanded. Therefore, it is important for clinicians to be knowledgeable about potential adverse reactions of this medication class. The goal of this review is to discuss the current understanding of cutaneous adverse reactions that may occur with common biologic medications utilized in the management of rheumatic diseases.

Recent Findings

A variety of cutaneous reactions have been reported in association with biologics commonly used to treat rheumatic diseases. Here, we review cutaneous reactions reported with tumor necrosis factor-α inhibitors, abatacept (co-stimulation blockade), CD20 inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, and IL-6 inhibitors. The side effects, in most cases, can be managed without discontinuation of the associated biologic medication. However, there are identified reactions that warrant discontinuation or adjustments in order to prevent additional and possibly permanent patient morbidity.

Summary

While causation is often difficult to prove when cutaneous side effects are observed in relation to biologic therapies, it is important for clinicians to be aware of characteristic or distinguishing cutaneous reactions in order to treat patients with rheumatic diseases safely and effectively.